FDA Hold Persists as Evenamide Death Imbalance Is Disclosed
Newron disclosed the FDA’s written rationale for maintaining the U.S. clinical hold on ENIGMA-TRS 2. The agency noted four deaths among evenamide-treated participants across the development program versus one among placebo participants and identified…
